Pharmacologic targeting of sirtuin and PPAR signaling improves longevity and mitochondrial physiology in respiratory chain complex I mutant Caenorhabditis elegans
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Mitochondrial respiratory chain (RC) diseases are highly morbid multi-systemic conditions for which few effective therapies exist. Given the essential role of sirtuin and PPAR signaling in mediating both mitochondrial physiology and the cellular response to metabolic stress in RC complex I (CI) disease, we postulated that drugs that alter these signaling pathways either directly (resveratrol for sirtuin, rosiglitazone for PPARγ, fenofibrate for PPARα), or indirectly by increasing NAD+ availability (nicotinic acid), might offer effective treatment strategies for primary RC disease. Integrated effects of targeting these cellular signaling pathways on animal lifespan and multi-dimensional in vivo parameters were studied in gas-1(fc21) relative to wild-type (N2 Bristol) worms. Specifically, animal lifespan, transcriptome profiles, mitochondrial oxidant burden, mitochondrial membrane potential, mitochondrial content, amino acid profiles, stable isotope-based intermediary metabolic flux, and total nematode NADH and NAD+ concentrations were compared. Shortened gas-1(fc21) mutant lifespan was rescued with either resveratrol or nicotinic acid, regardless of whether treatments were begun at the early larval stage or in young adulthood. Rosiglitazone administration beginning in young adult stage animals also rescued lifespan. All drug treatments reversed the most significant transcriptome alterations at the biochemical pathway level relative to untreated gas-1(fc21) animals. Interestingly, increased mitochondrial oxidant burden in gas-1(fc21) was reduced with nicotinic acid but exacerbated significantly by resveratrol and modestly by fenofibrate, with little change by rosiglitazone treatment. In contrast, the reduced mitochondrial membrane potential of mutant worms was further decreased by nicotinic acid but restored by either resveratrol, rosiglitazone, or fenofibrate. Using a novel HPLC assay, we discovered that gas-1(fc21) worms have significant deficiencies of NAD+ and NADH. Whereas resveratrol restored concentrations of both metabolites, nicotinic acid only restored NADH. Characteristic branched chain amino acid elevations in gas-1(fc21) animals were normalized completely by nicotinic acid and largely by resveratrol, but not by either rosiglitazone or fenofibrate. We developed a visualization system to enable objective integration of these multi-faceted physiologic endpoints, an approach that will likely be useful to apply in future drug treatment studies in human patients with mitochondrial disease. Overall, these data demonstrate that direct or indirect pharmacologic restoration of altered sirtuin and PPAR signaling can yield significant health and longevity benefits, although by divergent bioenergetic mechanism(s), in a nematode model of mitochondrial RC complex I disease. Thus, these animal model studies introduce important, integrated insights that may ultimately yield rational treatment strategies for human RC disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans
Murphy, C. T., McCarroll, S. A., Bargmann, C. I., Fraser, A., Kamath, R. S., Ahringer, J., Li, H., & Kenyon, C. (2003) · Nature · doi:10.1038/nature01789 · Cited by 2,280
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016 · cited 4×
“PPAR family nuclear receptor activity, which transcriptionally governs lipid and glucose homeostasis (Schupp & Lazar, 2010), may also be affected by NAD+ availability and metabolic stresses, such as NAD+-dependent SIRT1 deacetylation of PPAR-γ (Ahmadian et al, 2013).”
BackgroundInfluentialSirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008 · cited 1×
“…both mitochondrial physiology and the cellular response to metabolic stress in mitochondrial disease, namely sirtuins and the peroxisome-proliferator-activated receptor (PPAR) family of nuclear hormone receptors (Falk et al, 2011a; Hong et al, 2014; Houtkooper et al, 2012; Mouchiroud et al, 2013).”
BackgroundSirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868 · cited 1×
“1 (Wood et al, 2004) and daf-16 show 94.2% and 59.3% similarity to human SIRT1 and FOXO1, respectively.”
BackgroundInfluentialPrice, N. L., Gomes, A. P., Ling, A. J. Y., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.003 · Cited by 1,602 · cited 4×
“Alternatively, resveratrol may act on sirtuins and PGC1α indirectly via AMPK activation (Figure 8) (Price et al, 2012), although it is possible this is a dose-dependent effect of resveratrol and was not explicitly evaluated here.”
BackgroundInfluentialMouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210 · cited 1×
“…both mitochondrial physiology and the cellular response to metabolic stress in mitochondrial disease, namely sirtuins and the peroxisome-proliferator-activated receptor (PPAR) family of nuclear hormone receptors (Falk et al, 2011a; Hong et al, 2014; Houtkooper et al, 2012; Mouchiroud et al, 2013).”
BackgroundBitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205670200 · Cited by 1,002 · cited 19×
“Recognition of these secondary metabolite deficiencies in RC disease has important therapeutic implications, as we were able to show that treating the RC deficient patient cells for 24 hours with an NAD+ precursor, nicotinic acid, restored cellular NAD+ and NADH concentrations and improved total cellular mitochondrial…”
BackgroundInfluentialDirect inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans
Tullet, J. M. A., Hertweck, M., An, J. H., Baker, J., Hwang, J. Y., Liu, S., Oliveira, R. P., Baumeister, R., & Blackwell, T. K. (2008) · Cell · doi:10.1016/j.cell.2008.01.030 · Cited by 923 · cited 1×
“…signaling pathways (45% to 97% protein similarity) that directly modulate its function (DiMauro & Hirano, 2005; Dowell et al, 2003; Inoue et al, 2005; Mukhopadhyay et al, 2006; Murphy et al, 2003; Neumann-Haefelin et al, 2008; Tullet et al, 2008; Wang & Tissenbaum, 2006; Zhang et al, 2008).”
BackgroundThe secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899 · cited 1×
“As resveratrol is not a direct precursor for NAD+, its effects could reflect NAD+ salvage rather than increased de novo biosynthesis (Houtkooper et al, 2010; Pittelli et al, 2010) (Figure 8).”
BackgroundPARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation
Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R. H., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.004 · Cited by 837 · cited 3×
“…protein deacetylases whose activity depends directly on the relative availability of NAD+ and NADH (Bitterman et al, 2002; Canto et al, 2009), metabolites whose concentrations are indirectly affected by major NAD+ consuming enzymes such as the PARP family of DNA-repair enzymes (Bai et al, 2011).”
BackgroundInfluentialEffective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3
Khan, N. A., Auranen, M., Paetau, I., Pirinen, E., Euro, L., Forsström, S., Pasila, L., Velagapudi, V., Carroll, C. J., Auwerx, J., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403943 · Cited by 385
Rea, S. L., Ventura, N., & Johnson, T. E. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050259 · Cited by 383 · cited 1×
“…(Falk et al, 2008), neither treatment appeared to restore their low glutamate concentrations; this may potentially reflect concurrent changes in the RC mutant worm tricarboxylic acid cycle flux related to their increased glyoxylate shunt activity and ability to reduce fumarate (Rea et al, 2007).”
BackgroundNAD+-Dependent Activation of Sirt1 Corrects the Phenotype in a Mouse Model of Mitochondrial Disease
Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A. A., Li, W., Leoni, V., Schon, E. A., Dantzer, F., Auwerx, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.001 · Cited by 343 · cited 2×
“…investigations have shown benefits of targeted NAD+-repletion and NAD+-sparing strategies in a mouse model of cytochrome c oxidase deficiency (Cerutti et al, 2014), and nicotinamide riboside has also been used successfully to improve health in a rodent model of mitochondrial myopathy (Khan…”
BackgroundInhibition of Nicotinamide Phosphoribosyltransferase
Pittelli, M., Formentini, L., Faraco, G., Lapucci, A., Rapizzi, E., Cialdai, F., Romano, G., Moneti, G., Moroni, F., & Chiarugi, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.136739 · Cited by 189
Cited by
Regulation of nuclear epigenome by mitochondrial DNA heteroplasmy
Kopinski, P. K., Janssen, K. A., Schaefer, P. M., Trefely, S., Perry, C. E., Potluri, P., Tintos-Hernandez, J. A., Singh, L. N., Karch, K. R., Campbell, S. L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906896116 · Cited by 159
“NAD and NADH peak areas were integrated by the Shimadzu Lab Solution software with standard curves normalized to protein (31).”
MethodSelf-citationThe road ahead for health and lifespan interventions
Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., & de Cabo, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101037 · Cited by 118
Nutritional interventions in primary mitochondrial disorders: Developing an evidence base
Camp, K. M., Krotoski, D., Parisi, M. A., Gwinn, K. A., Cohen, B. H., Cox, C. S., Enns, G. M., Falk, M. J., Goldstein, A. C., Gopal-Srivastava, R., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.09.002 · Cited by 59
Self-citation
Metadata
- Authors
- McCormack, S., Polyak, E., Ostrovsky, J., Dingley, S. D., Rao, M., Kwon, Y. J., Xiao, R., Zhang, Z., Nakamaru-Ogiso, E., & Falk, M. J.
- Venue
- Mitochondrion
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 22
- Pages
- 45-59
- ISSN
- 1567-7249 (ISSN-L)
- OpenAlex
- W2028629517
- Cited by
- 45
- References
- 14
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.